Claims
- 1. A synthetic chimeric immunogenic peptide capable of eliciting HIV specific-antibodies, said synthetic peptide having the amino acid sequence of a functional T-cell epitope of the gag protein of HIV-1 linked to the amino acid sequence of a B-cell epitope of an envelope or gag protein of HIV-1 to provide an enhanced immune response to said B-cell epitope.
- 2. The peptide of claim 1 wherein the T-cell epitope has the amino acid sequence GPKEPFRDYVDRFYK (p24E) or GPKEPFRDYVDRFYKTLRAEQASQEV (HIV-1-p24).
- 3. The peptide of claim 2 wherein the B-cell epitope is a B-cell epitope of the gag protein linked to the C-terminus of the amino acid sequence of the T-cell epitope (p24E).
- 4. The peptide of claim 2 wherein the B-cell epitope is the BE3 sequence encompassing amino acid residues 727 to 751 of the HIV-1 envelope protein attached to the C-terminus of the amino acid sequence of the T-cell epitope (p24E) by a linker sequence.
- 5. The peptide of claim 2 wherein the B-cell epitope is a B-cell epitope linked to the C- or N-terminus of the amino acid sequence of the T-cell epitope (p24E) by a linker sequence.
- 6. The peptide of claim 5 wherein the linker sequence is PP.
- 7. The peptide of claim 6 wherein the B-ell epitope comprises BE3 connected to the N-terminus of the amino acid sequence of the T-cell epitope (p24E).
- 8. The peptide of claim 6 wherein said B-cell epitope comprises the ENV sequence encompassing the amino acid residues 256 to 273 of the HIV-1 envelope protein.
- 9. The peptide of claim 6 wherein the B-cell epitope comprises the V3A sequence encompassing the amino acid residues 308 to 327 of the variable loop of HIV-1 gP120 protein connected to the N-terminus of the amino acid sequence of the T-cell epitope (p24E).
- 10. An immunogenic composition, comprising, as the active component thereof, a synthetic chimeric immunogenic protein having the amino acid sequence of a T-cell epitope of the gag protein of HIV-1 linked to the amino acid sequence of a B-cell epitope of an envelope or gag protein of HIV-1.
- 11. The immunogenic composition of claim 10, wherein the T-cell epitope has the amino acid sequence GPKEPFRDYVDRFYK (p24E) or GPKEPFRDYVDRFYKTLRAEQASQEV (HIV-1- p24).
- 12. The immunogenic composition of claim 10 wherein the B-cell epitope is the BE3, ENV or V3A amino acid sequence.
- 13. The immunogenic composition of claim 12 wherein the B-cell epitope is joined to the C-terminus of the T-cell epitope.
- 14. The immunogenic composition of claim 12 or 13, wherein the B-cell epitope is joined to the C-terminus of the T-cell epitope by a linker sequence.
- 15. The immunogenic composition of claim 10, wherein the B-cell epitope is the BE3, ENV or V3A amino acid sequence joined to the T-cell epitope by a linker sequence comprising PP.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8910145 |
May 1989 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 07/768,608, filed as PCT/CA90/00146, May 3, 1990, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4925784 |
Crowl et al. |
May 1990 |
|
5013548 |
Haynes et al. |
May 1991 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
343132 |
May 1989 |
EPX |
1179687 |
Jul 1989 |
JPX |
2188639 |
Apr 1986 |
GBX |
Non-Patent Literature Citations (3)
Entry |
Cohen, 1993, "Jitters Jeopardize AIDS Vaccine Trial", Science 262: 980-981. |
Fox, 1994, "No Winners Against AIDS", Biotechnology 12:128. |
Sternberg, et al, 1987, "Prediction of antigenic determinants . . . "FEBS Letters 218(2): 231-237. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
768608 |
Aug 1992 |
|